Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | FURIN | P09958 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 3/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8171032 | 0.95 | EGFR (0.49) | PARP10FURINEGFRMAOBKDM4E | |
| SCHEMBL18210781 | 0.93 | EGFR (0.48) | PARP10EGFRMAOBKDM4EACHE | |
| SCHEMBL257928 | 0.93 | EGFR (0.48) | PARP10EGFRMAOBKDM4EACHE | |
| SCHEMBL470126 | 0.91 | ACHE (0.46) | PARP10EGFRMAOBACHEFPR2 | |
| SCHEMBL15448447 | 0.85 | FURIN (0.46) | PARP10FURINEGFRMAOBKDM4E | |
| SCHEMBL24969453 | 0.83 | ROCK1 (0.49) | PARP10FURINEGFRMAOBKDM4E | |
| SCHEMBL20217187 | 0.83 | FURIN (0.49) | PARP10FURINEGFRMAOBKDM4E | |
| SCHEMBL12807880 | 0.83 | FPR2 (0.40) | PARP10EGFRMAOBACHEFPR2 | |
| SCHEMBL20196968 | 0.83 | FPR2 (0.40) | PARP10EGFRMAOBACHEFPR2 | |
| SCHEMBL18175567 | 0.82 | EGFR (0.41) | PARP10EGFRMAOBKDM4EFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | ENYO PHARMA (FR) | 2023-10-12 | — | — | US | disclosed |
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | ENYO PHARMA (FR) | 2023-10-12 | — | — | US | disclosed |
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-09-26 | — | — | US | disclosed |
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-09-26 | — | — | US | disclosed |
| WO-2023083343-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-20210040059-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | Institut National de la Santé et de la Recherche Médicale (FR) | 2021-02-11 | — | — | US | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368449-B2 | 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | SCHERING CORPORATION | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | PARP10 1539/4885FURIN 3610/4885EGFR 2814/4885 |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | PARP10 669/4885FURIN 2253/4885EGFR 229/4885 |
| US-20210040059-A1 | NON-FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | PARP10 3260/4885FURIN 3085/4885EGFR 4227/4885 |
| US-11767316-B2 | Non-fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | PARP10 3260/4885FURIN 3085/4885EGFR 4227/4885 |
| US-20040220194-A1 | 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | ADORA2A, ADORA3, ADORA1 | PARP10 1701/4885FURIN 4409/4885EGFR 489/4885 |
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | PARP10 1526/4885FURIN 639/4885EGFR 776/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | PARP10 657/4885FURIN 4374/4885EGFR 184/4885 |
| US-20230321033-A1 | THIOPHEN COMPOUNDS FOR USE IN THE TREATMENT OF RENAL FIBROSIS | TST, TPMT, MMP1 | PARP10 3758/4885FURIN 2252/4885EGFR 1837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.